4.7 Article

Calcitonin Gene-Related Peptide Protects Against Cardiovascular Dysfunction Independently of Nitric Oxide In Vivo

期刊

HYPERTENSION
卷 77, 期 4, 页码 1178-1190

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/HYPERTENSIONAHA.120.14851

关键词

atherosclerosis; blood pressure; fibrosis; nitric oxide; vasodilation

资金

  1. MRC-DTP PhD studentship
  2. British Heart Foundation [PG/19/14/34268, PG/12/34/29557, PG/17/74/33111]
  3. British Biotechnology Science Research Council
  4. Auckland Medical Research Foundation Barbara Basham Doctoral Scholarship
  5. Arthritis Research UK
  6. British Heart Foundation [PG/17/74/33111] Funding Source: researchfish
  7. BBSRC [BB/P005616/1] Funding Source: UKRI

向作者/读者索取更多资源

CGRP plays a protective role in cardiovascular function by restoring blood pressure and preventing cardiovascular remodeling when nitric oxide production is diminished. Endogenous CGRP acts to protect cardiovascular function, while exogenous CGRP can rescue affected mice.
The neuropeptide CGRP (calcitonin gene-related peptide) is a potent vasodilator, with a cardioprotective role, although the precise mechanisms are unclear. Here we show the ability of endogenous and exogenous CGRP to restore blood pressure, when nitric oxide synthesis is blocked, in a model of cardiovascular disease associated with endothelial dysfunction and impaired nitric oxide production. Male wild-type and alpha CGRP knockout mice received L-nitro-arginine methyl ester (150 mg/kg in drinking water) to induce a sustained hypertension with evidence of cardiovascular remodeling. The hypertensive response was exacerbated in L-nitro-arginine methyl ester-treated alpha CGRP knockouts, indicating that endogenous alpha CGRP acts in a protective manner, when nitric oxide production is diminished. Exogenous CGRP rescued alpha CGRP knockout mice from both hypertension and cardiovascular remodeling. Further studies using a nonrecovery protocol with a CGRP receptor antagonist (BIBN4096 BS) revealed that CGRP acts via the canonical CGRP receptor (CLR [calcitonin-like receptor]/RAMP1 [receptor activity-modifying protein]); with no effect of an antagonist (AC187) of a second CGRP-responsive receptor (the amylin-1 receptor, CTR [calcitonin receptor]/RAMP1). Blood flow, in resistance vessels of the exteriorised mesentery, was investigated. Noradrenaline-induced vasoconstriction with recovery, in L-nitro-arginine methyl ester-treated wild-type mice. However, alpha CGRP knockout, or BIBN4096 BS-treated wild-type mice demonstrated a similar constrictor response to noradrenaline, but significantly impaired blood flow recovery. The combined findings highlight that alpha CGRP protects against cardiovascular dysfunction, signaling via the canonical CGRP receptor and acting when nitric oxide production is lost, such as in endothelial dysfunction associated with vascular disease. These in vivo results support the proposal that CGRP provides a novel treatment for cardiovascular disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据